QRxPharma hits on right dose
Monday, 20 April, 2009
Sydney’s QRxPharma has completed a Phase III pilot study comparing the efficacy of its lead dual-opioid with its constituent parts.
The lead drug, MoxDuo IR, a combination of morphine and oxycodone, was found to reduce pain significantly more than its component parts, and had fewer side effects than the two drugs administered together.
QRxPharama is in Phase III trials with the immediate release version of MoxDuo and in earlier stage trials for controlled release and intravenous administration. It is also being compared against Percocet in joint replacement surgery.
Besides its analgesia work, the company is also developing a known compound to activate the chaperone protein Torsin for neurological diseases such as Parkinson’s, and has an anti-haemorrhagic and an anti-coagulant derived from venoms in pre-clinical trials.
Common medications linked to adverse breast cancer outcomes
An international study has found concerning evidence about the impact of a range of common...
Saliva-based biosensor could improve heart failure detection
Scientists have created a biosensor that can rapidly detect the heart failure biomarker S100A7 in...
Melanoma-causing mutation can lie dormant in healthy skin
Researchers found many examples of the mutation in normal skin, including skin next to a mole and...
